相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The Therapeutic Effect of Anti-HER2/neu Antibody Depends on Both Innate and Adaptive Immunity
SaeGwang Park et al.
CANCER CELL (2010)
Monoclonal antibodies: versatile platforms for cancer immunotherapy
Louis M. Weiner et al.
NATURE REVIEWS IMMUNOLOGY (2010)
Phase I Study of ch14.18 With Granulocyte-Macrophage Colony-Stimulating Factor and Interleukin-2 in Children With Neuroblastoma After Autologous Bone Marrow Transplantation or Stem-Cell Rescue: A Report From the Children's Oncology Group
Andrew L. Gilman et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Monoclonal antibodies for cancer immunotherapy
Louis M. Weiner et al.
LANCET (2009)
MF59 Emulsion Is an Effective Delivery System for a Synthetic TLR4 Agonist (E6020)
Barbara C. Baudner et al.
PHARMACEUTICAL RESEARCH (2009)
Cross-Talk between TLR4 and FcγReceptorIII (CD16) Pathways
Daniel Rittirsch et al.
PLOS PATHOGENS (2009)
Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage FcγRI, FcγRIII, and FcγRIV
Veronique Minard-Colin et al.
BLOOD (2008)
Improved Tumor Immunity Using Anti-Tyrosinase Related Protein-1 Monoclonal Antibody Combined with DNA Vaccines in Murine Melanoma
Yvonne M. Saenger et al.
CANCER RESEARCH (2008)
Dose and schedule study of panitumumab monotherapy in patients with advanced solid malignancies
Louis M. Weiner et al.
CLINICAL CANCER RESEARCH (2008)
Antibody association with HER-2/neu-targeted vaccine enhances CD8+ T cell responses in mice through Fc-mediated activation of DCs
Peter S. Kim et al.
JOURNAL OF CLINICAL INVESTIGATION (2008)
Synthetic Toll-like receptor 4 agonist enhances vaccine efficacy in an experimental model of toxic shock syndrome
Garry L. Morefield et al.
CLINICAL AND VACCINE IMMUNOLOGY (2007)
Phase I trial of toll-like receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non-hodgkin's lymphoma
John R. Leonard et al.
CLINICAL CANCER RESEARCH (2007)
E6020: a synthetic Toll-like receptor 4 agonist as a vaccine adjuvant
Sally T. Ishizaka et al.
EXPERT REVIEW OF VACCINES (2007)
Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy
Lionel Apetoh et al.
NATURE MEDICINE (2007)
Augmented HER-2-Specific immunity during treatment with trastuzumab and chemotherapy
Clare Taylor et al.
CLINICAL CANCER RESEARCH (2007)
Induction of adaptive anti-HER2/neu immune responses in a phase 1B/2 trial of 2B1 bispecific murine monoclonal antibody in metastatic breast cancer (E3194):: A trial coordinated by the Eastern Cooperative Oncology Group
Hossein Borghaei et al.
JOURNAL OF IMMUNOTHERAPY (2007)
The high-affinity IgG receptor, FcγRI, plays a central role in antibody therapy of experimental melanoma
L Bevaart et al.
CANCER RESEARCH (2006)
HER2-targeted therapy reduces incidence and progression of midlife mammary tumors in female murine mammary tumor virus huHER2-transgenic mice
D Finkle et al.
CLINICAL CANCER RESEARCH (2004)
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer
D Cunningham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Novel synthetic LPS receptor agonists boost systemic and mucosal antibody responses in mice
M Przetak et al.
VACCINE (2003)
Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma
WK Weng et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Human ErbB-2 (Her-2) transgenic mice: A model system for testing Her-2 based vaccines
MP Piechocki et al.
JOURNAL OF IMMUNOLOGY (2003)
CTLA-4: new insights into its biological function and use in tumor immunotherapy
JG Egen et al.
NATURE IMMUNOLOGY (2002)
Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene
G Cartron et al.
BLOOD (2002)
A novel class of endotoxin receptor agonists with simplified structure, toll-like receptor 4-dependent immunostimulatory action, and adjuvant activity
LD Hawkins et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2002)
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
RA Clynes et al.
NATURE MEDICINE (2000)
分享论文
